MBX Biosciences, Inc. (MBX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.
MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 142% in MBX Biosciences, Inc. (MBX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet
The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to a 228.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 280.1% in MBX Biosciences, Inc. (MBX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
In the past week or so, some public offerings of stock prompted big insider buying.
MBX Biosciences, Inc. - Special Call
MBX Biosciences, Inc. - Special Call Company Participants Jim DeNike Peter Hawryluk - CEO, President & Director Salomon Azoulay - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Trevor Allred - Oppenheimer & Co. Inc., Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Presentation Operator Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded.
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet
The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
